CPRX vs. HRMY

Last updated Apr 1, 2026

Compare and contrast key facts about Catalyst Pharmaceuticals, Inc. (CPRX) and Harmony Biosciences Holdings, Inc. (HRMY).

Performance

CPRX vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

CPRX vs. HRMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020
CPRX Catalyst Pharmaceuticals, Inc.	6.08%	11.84%	24.15%	-9.62%	174.74%	102.69%	-7.73%
HRMY Harmony Biosciences Holdings, Inc.	-25.15%	8.75%	6.53%	-41.38%	29.22%	17.95%	-2.32%

Fundamentals

Market Cap CPRX : $3.15B HRMY : $1.64B
EPS CPRX : $1.68 HRMY : $3.33
PE Ratio CPRX : 14.71 HRMY : 8.41
PEG Ratio CPRX : 0.26 HRMY : 0.08
PS Ratio CPRX : 5.35 HRMY : 1.89
PB Ratio CPRX : 3.30 HRMY : 1.89
Total Revenue (TTM) CPRX : $588.99M HRMY : $868.45M
Gross Profit (TTM) CPRX : $726.82M HRMY : $670.11M
EBITDA (TTM) CPRX : $257.78M HRMY : $238.25M

Returns By Period

In the year-to-date period, CPRX achieves a 6.08% return, which is significantly higher than HRMY's -25.15% return.

CPRX

• 1D: 4.12%
• 1M: 7.28%
• YTD: 6.08%
• 6M: 25.69%
• 1Y: 2.10%
• 3Y*: 14.30%
• 5Y*: 40.58%
• 10Y*: 35.35%

HRMY

• 1D: 4.13%
• 1M: -1.86%
• YTD: -25.15%
• 6M: 1.63%
• 1Y: -15.61%
• 3Y*: -4.98%
• 5Y*: -2.68%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CPRX vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX

CPRX Risk / Return Rank: 41
CPRX Sharpe Ratio Rank: 44
CPRX Sortino Ratio Rank: 38
CPRX Omega Ratio Rank: 37
CPRX Calmar Ratio Rank: 42
CPRX Martin Ratio Rank: 41

HRMY

HRMY Risk / Return Rank: 25
HRMY Sharpe Ratio Rank: 25
HRMY Sortino Ratio Rank: 25
HRMY Omega Ratio Rank: 24
HRMY Calmar Ratio Rank: 28
HRMY Martin Ratio Rank: 25

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CPRX	HRMY	Difference
Sharpe ratio Return per unit of total volatility	0.06	-0.37	+0.43
Sortino ratio Return per unit of downside risk	0.32	-0.24	+0.57
Omega ratio Gain probability vs. loss probability	1.04	0.96	+0.08
Calmar ratio Return relative to maximum drawdown	0.01	-0.45	+0.46
Martin ratio Return relative to average drawdown	0.02	-0.98	+1.00
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CPRX vs. HRMY - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.06, which is higher than the HRMY Sharpe Ratio of -0.37. The chart below compares the historical Sharpe Ratios of CPRX and HRMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CPRX	HRMY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.06	-0.37	+0.43
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.85	-0.05	+0.90
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.56	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	-0.09	+0.17

Correlation

The correlation between CPRX and HRMY is 0.35, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CPRX vs. HRMY - Dividend Comparison

Neither CPRX nor HRMY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CPRX vs. HRMY - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for CPRX and HRMY.

Drawdown Indicators

	CPRX	HRMY	Difference
Max Drawdown Largest peak-to-trough decline	-94.25%	-68.48%	-25.77%
Max Drawdown (1Y) Largest decline over 1 year	-27.29%	-34.49%	+7.20%
Max Drawdown (5Y) Largest decline over 5 years	-45.37%	-68.48%	+23.11%
Max Drawdown (10Y) Largest decline over 10 years	-64.87%	—	—
Current Drawdown Current decline from peak	-5.89%	-54.01%	+48.12%
Average Drawdown Average peak-to-trough decline	-52.51%	-34.74%	-17.77%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.10%	15.95%	-0.85%

Volatility

CPRX vs. HRMY - Volatility Comparison

Catalyst Pharmaceuticals, Inc. (CPRX) has a higher volatility of 10.39% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 8.18%. This indicates that CPRX's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CPRX	HRMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.39%	8.18%	+2.21%
Volatility (6M) Calculated over the trailing 6-month period	23.71%	31.02%	-7.31%
Volatility (1Y) Calculated over the trailing 1-year period	34.96%	41.98%	-7.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	48.24%	50.63%	-2.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.81%	52.83%	+9.98%

Financials